Why NeoGenomics, Inc.’s (NEO) Stock Is Down 5.61%
As of Thursday, October 29, NeoGenomics, Inc.’s NEO share price has dipped by 5.61%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients’ oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
Commentary & Analysis
Why NeoGenomics, Inc.’s (NEO) Stock Is Down 9.51%
As of Tuesday, October 06, NeoGenomics, Inc.’s NEO share price has dipped by 9.51%, which has investors questioning if this is right time to buy.Michael Rose
Why NeoGenomics, Inc.’s (NEO) Stock Is Down 12.25%
As of Tuesday, October 06, NeoGenomics, Inc.’s NEO share price has dipped by 12.25%, which has investors questioning if this is right time to buy.Omar Beirat
Which Is a Better Investment, Molina Healthcare, Inc. or NeoGenomics, Inc. Stock?
Learn more about whether Molina Healthcare, Inc. or NeoGenomics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Tudor Pop
Which Is a Better Investment, NeoGenomics, Inc. or Universal Health Services, Inc. Stock?
Learn more about whether NeoGenomics, Inc. or Universal Health Services, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Tudor Pop
Financial Summary
| Share Statistics | NEO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,219.0 | $2,049.0 | 56% |
|
| Shares Out (Mil) | 128.6 | 79.7 | 67% |
|
| Institutional Ownership | 98.0% | 85.9% | 76% |
|
| Float (Mil) | 117.9 | 58.3 | 64% |
|
| Beta | 1.78 | 0.78 | 88% |
|
| Avg Daily Volume (000s) | 2,042 | 661 | 81% |
|
| Price Change (52-week) |
75.4% | 83.6% | 92% |
|
| Growth | NEO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 10.4% | 10.4% | 60% |
|
| Net Income (5yr) | (94.3%) | (1.1%) | 2% |
|
| EPS (5yr) | (89.1%) | 1.2% | 1 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (33.8%) | (17.3%) | 16% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 11 | 10 | 11 | |
| Current EPS | $0.065 | $0.204 | $0.315 | |
| Month Ago EPS | $0.069 | $0.183 | $0.338 | |
| # Rev Up | 2 | 4 | 0 | |
| # Rev Down | 1 | 1 | 3 | |
| Three Months Ago EPS | $0.069 | $0.183 | $0.338 | |
| Year/Year Chg | (208.3%) | (124.2%) | (149.8%) | |
| Financials | NEO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $788 | $1,532 | 47% |
|
| Net Income (TTM) (Mil) | ($32) | $31 | 20% |
|
| EPS (TTM) | ($0.250) | $0.300 | 32% |
|
| Operating Cash Flow (TTM) (Mil) | $4 | $168 | 36% |
|
| Net Cash Flow (TTM) (Mil) | ($25) | $2 | 25% |
|
| Long-Term Debt (Q1) (Mil) | $443 | $394 | 57% |
|
| Enterprise Value (Q1) (Mil) | $2,559 | $2,409 | 52% |
|
| Valuation | NEO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.77 | 2.97 | 65% |
|
| P/E | na | 28.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | NEO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 44.8% | 27.0% | 56% |
|
| Net Margin | (4.1%) | 1.3% | 26% |
|
| ROA | (2.3%) | 2.2% | 33% |
|
| ROE | (3.9%) | 6.8% | 31% |
|
| Liabilities to Assets | 41.9% | 61.5% | 33% |
|
| F-Score | 5 | 5 | 50% |
|
NeoGenomics, Inc. did not pass any screens on 11/4/2026.
